Unfortunately, we could not get stock quote PIRS this time.
Investor Relations | SEC Filings | Key Metrics | @YMB | @SA | @Benzinga | @iHub
Original Content from StoryTrading:
  • Good Day for our Story Trades SLTD HOTR PIRS RGSE JAKK (7/22/2015) -  Today was our best day in many weeks. * PIRS was up 4% on an upgrade from Roth Capital. It had a record volume day. Kudos to James Evans for finding this opportunity early. We are looking for a swing to $7 * SLTD was up 24% on a pre-announcement of sequential revenue growth of 95%. Trading volume today was More »
  • PIRS: Roth Capital Initiates Coverage with a $7 target (7/22/2015) -  Roth Capital just came out this morning with a price target of $7 for PIRS, 159% higher than where PIRS closed yesterday. A direct link to the report is not yet available but a screen shot of the first two pages can be seen below: I like this comment from their research report: ” Pieris secured a monopoly to an entire More »
  • Interview of PIRS CEO, Steve Yoder. (7/21/2015) -  A quick update on the recently initiated storytrade, PIRS: Wall Street Analyzer released a podcast interview of the CEO of PIRS Steve Yoder yesterday.  Please find the link below.  http://wallstreetanalyzer.com/pieris-pharma-nasdaqpirs-ceo-interview/ A couple of highlights: The company is in the process of moving their corporate headquarters from Frankfurt Germany to Boston Massachusetts USA.  Boston is one of the largest biotech hotbeds in More »
  • PIERIS PHARMACEUTICALS – Undiscovered Immunotherapy Play (7/17/2015) -  The Story Pieris Pharmaceuticals (PIRS)  is a clinical stage bio-pharmaceutical firm that develops a bio-class of therapeutics called anticalins, which bind, store and transport a wide variety of molecules. Anticalins are currently being tested against, Anemia, Asthma,and most importantly cancer Immunotherapy.  Immunotherapy biotech stocks have been red hot in the past year, with many rising 10 fold.  RCPT, KITE, TRIL, AFMD More »